Summary
Stryker Corporation (SYK) reported strong performance in its Q3 2008 filing, with net sales increasing by 14% year-over-year to $1.65 billion. This growth was driven by robust performance in both its Orthopaedic Implants and MedSurg Equipment segments, with notable strength in knee implants and surgical equipment. Net earnings from continuing operations saw a significant 20% increase to $273.8 million, translating to diluted EPS of $0.66. The company also highlighted a substantial share repurchase program, demonstrating a commitment to returning value to shareholders. However, investors should note the ongoing challenges related to investments in auction-rate securities, which are currently illiquid due to market conditions, although the company believes this will not impact its operational funding. Operationally, Stryker demonstrated solid execution across its product lines, with significant contributions from both domestic and international markets. The company's outlook for the full year 2008 remains optimistic, projecting a 22% increase in diluted EPS, indicating continued confidence in its growth trajectory despite broader economic uncertainties. The company is also proactively addressing regulatory matters and quality systems improvements, showcasing a commitment to compliance and operational excellence.
Financial Highlights
27 data points| Revenue | $1.65B |
| Cost of Revenue | $541.70M |
| Gross Profit | $1.11B |
| R&D Expenses | $92.60M |
| SG&A Expenses | $644.80M |
| Operating Expenses | $747.20M |
| Operating Income | $364.10M |
| Net Income | $273.80M |
| EPS (Basic) | $0.67 |
| EPS (Diluted) | $0.66 |
| Shares Outstanding (Basic) | 409.70M |
| Shares Outstanding (Diluted) | 415.80M |
Key Highlights
- 1Net sales increased by 14% to $1.65 billion in Q3 2008 compared to the prior year period.
- 2Net earnings from continuing operations rose by 20% to $273.8 million, with diluted EPS of $0.66.
- 3Strong growth was observed in both the Orthopaedic Implants (12% increase) and MedSurg Equipment (16% increase) segments.
- 4The company repurchased 9.1 million shares of common stock for $596 million during the third quarter of 2008.
- 5Domestic sales increased by 13% year-over-year, while international sales grew by 15% reported and 10% on a constant currency basis.
- 6The company expects full-year 2008 diluted EPS to approximate $2.88, a 22% increase over 2007.
- 7Investments in auction-rate securities remain illiquid due to market conditions, valued at $152.1 million as of September 30, 2008.